1,128
Views
28
CrossRef citations to date
0
Altmetric
Applications and Case Studies

Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros

, , &
Pages 875-885 | Received 01 Nov 2010, Published online: 08 Oct 2012

REFERENCES

  • Berman , D. and Crump , K. 2003 . “Technical Support Document for a Protocol to Assess Asbestos-Related Risk: Final Draft,” . Technical Report, United States Environmental Protection Agency.
  • Bottomley , A. , Coens , C. , Efficace , F. , Gaafar , R. , Manegold , C. , Burgers , S. , Vincent , M. , Legrand , C. , van Meerbeeck , J. and EORTC–NCIC . 2007 . “Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma,” . Journal of Clinical Oncology , 25 : 5770 – 5776 .
  • Brooks , S. and Gelman , A. 1997 . “General Methods for Monitoring Convergence of Iterative Simulations,” . Journal of Computational and Graphical Statistics , 7 : 434 – 455 .
  • Cook , D. , Kieschnick , R. and McCullough , B. 2008 . “Regression Analysis of Proportions in Finance With Self Selection,” . Journal of Empirical Finance , 15 : 860 – 867 .
  • Czado , C. and Santner , T. 1992 . “The Effect of Link Misspecification on Binary Regression Inference,” . Journal of Statistical Planning and Inference , 33 : 213 – 231 .
  • Eli Lilly and Company . 2010 . “Alimta Prescribing Information,” . Available at http://pi.lilly.com/us/alimta-pi.pdf
  • Eli Lilly and Company . 2011 . “Information for Patients and Caregivers, Alimta® (Pemetrexed for Injection),” . available at http://pi.lilly.com/us/alimta-ppi.pdf
  • Fairclough , D. 2004 . “Patient Reported Outcomes as Endpoints in Medical Research,” . Statistical Methods in Medical Research , 13 : 115 – 138 .
  • Galateau-Sallé , F. 2006 . “Epidemiology of Mesothelioma,” . In Pathology of Malignant Mesothelioma , 1 – 10 . ed. F. Galateau-Sallé, London : Springer .
  • Ghosh , P. and Albert , P. 2009 . “A Bayesian Analysis for Longitudinal Semicontinuous Data With an Application to an Acupunture Clinical Trial,” . Computational Statistics and Data Analysis , 53 : 699 – 706 .
  • Ghosh , S. , Gelfand , A. , Clark , J. and Zhu , K. 2011 . “The k-ZIG: Flexible Modeling for Zero-Inflated Counts,” . Technical Report, Department of Statistics, Duke University.
  • Hanson , T. , Branscum , A. and Johnson , W. 2011 . “Predictive Comparison of Joint Longitudinal-Survival Modeling: A Case Study Illustrating Competing Approaches,” . Lifetime Data Analysis , 17 : 3 – 28 .
  • Hatfield , L. , Hodges , J. and Carlin , B. 2011 . “Bayesian Learning in Hierarchical Joint Models,” . Technical Report, Division of Biostatistics, School of Public Health, University of Minnesota.
  • Hollen , P. , Gralla , R. , Liepa , A. , Symanowski , J. and Rusthoven , J. 2006 . “Measuring Quality of Life in Patients With Pleural Mesothelioma Using a Modified Version of the Lung Cancer Symptom Scale (LCSS): Psychometric Properties of the LCSS-Meso,” . Supportive Care in Cancer , 14 : 11 – 21 .
  • Ibrahim , J. , Chen , M.-H. and Sinha , D. 2002 . Bayesian Survival Analysis , New York : Springer-Verlag .
  • Lachenbruch , P. 2002 . “Analysis of Data With Excess Zeros,” . Statistical Methods in Medical Research , 11 : 297 – 302 .
  • Laffler , M. 2009, September 16 . “FDA Will Revisit Appropriate use of PFS Endpoints at Advisory Committee,” . The Pink Sheet Daily , , Article No. 14090916003.
  • Lipscomb , J. , Reeve , B. , Clauser , S. , Abrams , J. , Bruner , D. , Burke , L. , Denicoff , A. , Ganz , P. , Gondek , K. , Minasian , L. , O’Mara , A. , Revicki , D. , Rock , E. , Rowland , J. , Sgambati , M. and Trimble , E. 2007 . “Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward,” . Journal of Clinical Oncology , 25 : 5133 – 5140 .
  • Lu , C. and Meeker , W. 1993 . “Using Degradation Measures to Estimate a Time-to-Failure Distribution,” . Technometrics , 35 : 161 – 174 .
  • Lunn , D. 2003 . “WinBUGS Development Interface (WBDev),” . ISBA Bulletin , 10 : 10 – 11 .
  • Neuhaus , J. 1999 . “Bias and Efficiency Loss Due to Misclassified Responses in Binary Regression,” . Biometrika , 86 : 843 – 855 .
  • Niyikiza , C. , Baker , S. , Seitz , D. , Walling , J. , Nelson , K. , Rusthoven , J. , Stabler , S. , Paoletti , P. , Calvert , A. and Allen , R. 2002 . “Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity From Pemetrexed Therapy,” . Molecular Cancer Therapeutics , 1 : 545 – 552 .
  • Pregibon , D. 1980 . “Goodness of Link Tests for Generalized Linear Models,” . Applied Statistics , 29 : 15 – 24 .
  • Ray , M. and Kindler , H. L. 2009 . “Malignant Pleural Mesothelioma,” . Chest , 136 : 888 – 896 .
  • Rizipoulos , D. , Verbeke , G. and Molenberghs , G. 2008 . “Shared Parameter Models Under Random Effects Misspecification,” . Biometrika , 95 : 63 – 74 .
  • Rizopoulos , D. , Verbeke , G. , Lesaffre , E. and Vanrenterghem , Y. 2008 . “A Two-Part Joint Model for the Analysis of Survival and Longitudinal Binary Data With Excess Zeros,” . Biometrics , 64 : 611 – 619 .
  • Rock , E. , Kennedy , D. , Furness , M. , Pierce , W. , Pazdur , R. and Burke , L. 2007 . “Patient-Reported Outcomes Supporting Anticancer Product Approvals,” . Journal of Clinical Oncology , 25 : 5094 – 5099 .
  • Rusch , V. 1995 . “A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma. From the International Mesothelioma Interest Group,” . Chest , 108 : 1122 – 1128 .
  • Spiegelhalter , D. , Thomas , A. , Best , N. and Lunn , D. 2004 . WinBUGS User Manual , Version 1.4 ed., Cambridge: MRC Biostatistics Unit, Institutes of Public Health
  • Sturtz , S. , Ligges , U. and Gelman , A. 2005 . “R2WinBUGS: A Package for Running WinBUGS From R,” . Journal of Statistical Software , 12 : 1 – 16 .
  • Tsiatis , A. and Davidian , M. 2004 . “Joint Modeling of Longitudinal and Time-to-Event Data: An Overview,” . Statistica Sinica , 14 : 809 – 834 .
  • U.S. Food and Drug Administration . 2004 . “Alimta Label and Approval History, NDA 021677,” . available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
  • Vogelzang , N. , Rusthoven , J. , Symanowski , J. , Denham , C. , Kaukel , E. , Ruffie , P. , Gatzemeier , U. , Boyer , M. , Emri , S. , Manegold , C. , Niyikiza , C. and Paoletti , P. 2003 . “Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma,” . Journal of Clinical Oncology , 21 : 2636 – 2644 .
  • Wagner , J. , Sleggs , C. and Marchand , P. 1960 . “Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province,” . British Journal of Industrial Medicine , 17 ( 4 ) : 260 – 271 .
  • Wang , X. and Dey , D. 2010 . “Generalized Extreme Value Regression for Binary Response Data: An Application to B2B Electronic Payments System Adoption,” . The Annals of Applied Statistics , 4 : 2000 – 2003 .
  • Zucali , P. , De Vincenzo , F. , Simonelli , M. and Santoro , A. 2009 . “Future Developments in the Management of Malignant Pleural Mesothelioma,” . Expert Review of Anticancer Therapy , 9 : 453 – 467 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.